It's been just over a year since the CDC came out with guidelines for using HIV-drug Truvada as pre-exposure prophylaxis (PrEP) in preventing HIV. Where are we now? VICE created a thoughtful documentary on the topic that interviews Truvada advocates, critics, and HIV researchers. Stopping HIV with the Truvada Revolution : Part 1; Part 2; Part 3 [more inside]
BuzzFeed LGBT editor Saeed Jones joins journalists Steven Thrasher and Dave Tuller to discuss sex, gay men, and what we are (and aren’t) doing. (SL Buzzfeed)
This month, the US Public Health Service released (PDF) the first comprehensive clinical practice guidelines for PrEP (Pre-Exposure Prophylaxis) which outlines the criteria for determining a person’s HIV risk and indications for PrEP use. (PrEP FAQ) The CDC states, "When taken consistently, PrEP has been shown to reduce the risk of HIV infection in people who are at high risk by up to 92%. PrEP is much less effective if it is not taken consistently." The FDA's approved drug — Truvada — that was previously approved for H.I.V. treatment in 2004, is now approved it for prevention of HIV transmission. (Truvada previously) [more inside]
[Eleven] days ago, The New Yorker’s Daily Comment blog published an essay by Michael Specter titled “What Young Gay Men Don’t Know About Aids,” in which Specter points to the increase of “unprotected anal intercourse among gay men,” claims that “the rates of HIV infection will surely follow,” and then identifies the cause of this shift as the ignorance of my generation, who weren’t around to see the AIDS epidemic for themselves. The piece is a call to arms of sort, stating the need for increased public funding for HIV/AIDS prevention, and concludes by quoting Larry Kramer’s famous 1983 warning, “1,112 and Counting.” It’s a familiar argument—one that, in my lifetime, I have heard repeated ad nauseam and, I fear, largely misses what AIDS means to me and many other young gay men.
An article published in the New England Journal of Medicine online edition today announced study results that the use daily of antiretroviral medicine reduced rate the acquisition of HIV infection. The New York Times coverage highlighted the result that the preexposure prophylaxis protected more than 90% of study participants who took the medicine every day, as prescribed. An editorial in the NEJM noted, however, that compliance was problematic, with only 44%of study participants protected overall. [more inside]